

Reversal Effect of Doxorubicin on Arteether Resistance in Rodent Malaria Parasite *Plasmodium vinckei*

Ramesh Chandra* and Puri SK

Division of Parasitology, Central Drug Research Institute, India

*Corresponding author: Ramesh Chandra, Division of Parasitology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh 226031, India, E-mail: rameshcdri1@gmail.com

Received date: 26 May 2015; Accepted date: 29 July 2015; Published date: 08 August 2015.

Citation: Chandra R, Puri SK (2015) Reversal Effect of Doxorubicin on Arteether Resistance in Rodent Malaria Parasite *Plasmodium vinckei*. J Drug Res Dev 1(1): doi <http://dx.doi.org/10.16966/2470-1009.104>

Copyright: © 2015 Chandra R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Artemisinin based combination therapies may effectively reverse the resistance in malaria parasite by reversal agents. Here, we are first time showing arteether (ART) drug resistance reversal in *Plasmodium vinckei* by using Doxorubicin (DOXO). We hypothesized that oxidative stress catabolism may interfere with DOXO, resulting increased the efficacy of ART. We show the synergetic effect of DOXO with ART by complete suppression of parasitemia till day 10 post treatment. In addition, results also showed higher Activity Enhancement Index (AEI) of ART. These studies propose the possibility of ART drug combination that may be helpful in reducing the chance of resistance development.

Keywords: α/β Arteether; Activity enhancement index; Doxorubicin combination; *Plasmodium vinckei*; Resistance reversal

Introduction

Artemisinin and its derivatives are truly remarkable drug and the standard of care for malaria over about quarter a century. These are the most effective antimalarial drugs that act against the chloroquine resistant *P. falciparum* [1]. The mechanism of action, involves the breaking of endoperoxide bridge and generating a highly reactive free radical by activation of parasitic iron. The activated endoparasites form a covalent bond with parasite proteins killing the parasite [2,3]. Artemisinin-based combination therapies (ACTs) [4-6] have now become the standard of care for malaria chemotherapy, against malarial parasite resistance to existing antimalarial drugs [7,8]. α/β arteether is a semi synthetic derivative of artemisinin, acting as the blood schizontocidal agents at the erythrocytic stage of malaria in blood. ART is registered in India [9] and is now being used for second line of treatment for chloroquine-resistant *P. falciparum* malaria including cerebral malaria [10-12]. This is most effective against chloroquine resistance against *P. yoelii* [13] *P. vinckei* [14] and *P. falciparum* [1,11,12]. ART based combination have been studied with Curcumin in *P. berghei* [15]. ART and sulfadoxine-pyrimethamine for *P. falciparum* is the most effective combined treatment [16]. Limited studies have been carried out that proposes ART drug resistance reversal, which in turn can be more promising. Here, we first time showed the ART drug resistance reversal in *P. vinckei* by using anticancer drug Doxorubicin (DOXO). The DOXO is an anthracycline antibiotic that has been employed as anticancer drugs and is routinely being used in the clinic as chemotherapeutic agents [17]. The mechanism of action of DOXO involves oxidative stress, inhibition of DNA polymerases, DNA topoisomerase II, and DNA methyltransferase [18-20].

Materials and Methods

Mice and parasites

Swiss albino mice weighing 24-26 g were obtained from the Division of Laboratory Animals, Central Drug Research Institute, Lucknow, India. The mice were sheltered in the animal facility at the Institute and maintained on commercial pellet diet and water *ad libitum* under standard housing conditions. Ethical guidelines on handling, care and use

of experimental animals were followed during the conduct of the study. We have used stable PvAR parasite for this study as described before [21,22]). The stable selected ART resistant *Plasmodium vinckei* (PvAR) was maintained by drug pressure, which showed >24- fold resistance at the time of study [23,24]. However, inoculum for each experiment was obtained from infected mice left untreated for one passage.

Drugs and reversal study

Resistance reversal studies were performed by pharmacological agents in combination with ART. Six mice per drug combination were inoculated by an intraperitoneal (i.p.) injection of 1×10^6 infected erythrocytes [24]. The treatment was started 4 h later and continued for the subsequent 4 days [24]. DOXO was obtained from Dabur Pharma Ltd, India. The antimalarial drugs artemisinin derivative α/β ART obtained from Medicinal Chemistry Division, CDRI. ART was dissolved in ground nut oil and administered by intramuscular (i.m.) injection. While partner drugs were diluted in aqueous solution and administered by i.p. routes. Parasitemia was recorded on days 4, 7, 10, 14 and 17 and compared to the group treated with ART alone.

Determination of $ED_{10}/ED_{50}/ED_{90}$

Group of mice was inoculated with 1×10^6 parasitized cells and treatment was administered for 4 days. Microscopic slides were observed on day 4. The suppression in parasitemia was counted with comparison with vehicle control. ED_{50}/ED_{90} value was calculated by non-linear regression analysis [23]. Parasitemia was monitored in thin blood smears, fixed in methanol and stained with Giemsa (Merck, Germany) for 30 min. The slides were washed in tap water, dried and examined in at least 20 fields per slide using the 100X microscope to determine the percentage of infected erythrocytes [23].

Evaluation of drug effect

Activity enhancement index (AEI) was determined for synergetic effect of partner drug as described before [25,26]), which was calculated as follows: ED_{90} of ART alone/ ED_{90} of ART in combination with partner drug. An AEI of >1 indicates activity enhancement, and an AEI of <1

indicates activity reduction. An AEI of less than 2.0 was considered insignificant.

Results and Discussion

Our previous study has shown that higher antioxidant enzyme and glutathione may be correlated with ART resistance in *P. vinckei* [23,24]. We hypothesized that glutathione and oxidative stress catabolism may interfere with DOXO, resulting in an increased efficacy of ART in PvAR parasite. To investigate the combination effect of antitumor drug DOXO, we have injected it to infected mice alone in combination with ART for 4 days to PvAR infected mice. DOXO was treated to infected mice at doses level 5 mg/kg in combination with 3 mg/kg of ART [23]. Parasitemia was recorded on days 4, 7, 10 and 14 and compared with group treated with ART alone. The result showed that none of the mice developed parasitemia up to day 10 in combine group and 2 mice became patent on day 14. All mice became patent on day 10 (Table 1). However, mice treated with DOXO or ART alone show the parasitemia on day 4. This result indicates that DOXO has synergetic effect on mice treated with ART as evidenced by their extended day of suppression of parasitemia as compared to the group treated alone (Table 1).

To evaluate the AEI of ART, first we determined ED₅₀/ED₉₀ ART alone for which results are 4.49 and 17.23 mg/kg respectively (Table 2). We next evaluated the ED₁₀/ED₅₀/ED₉₀ of DOXO, at four serial dose levels i.e. 4, 2, 1, 0.5 mg/kg and vehicle control for four consecutive day's treatment to each group. The results showed that ED₁₀/ED₅₀/ED₉₀ values for DOXO against PvAR strain are 0.39, 2.02 and 3.65 mg/kg respectively (Table 2). Next we evaluated ED₅₀/ED₉₀ of ART in combination with DOXO. We have chosen two sub-curative dose of DOXO 0.4 and 2 mg/kg, which are ED₁₀ and ED₅₀ if used alone respectively (Table 2). Each group was infected with PvAR parasites and treated with ART at dose levels 10, 3, 1, 0.3 & 0.1 mg/kg for four consecutive days in combination with 0.4 or 2 mg/kg DOXO. The results conclude that ED₅₀/ED₉₀ of ART was reduced from 4.49 and 17.23 mg/kg to 3.19 and 7.92 at dose 0.4 mg/kg DOX, and 0.07 and 1.90 at dose 2 mg/kg DOXO (Table 2). Activity Enhancement Index (AEI) of ART was significantly higher 2.17 and 9.07 combination with DOXO at 0.4 and 2 mg/kg respectively (Table 2).

These results further suggested the synergistic effect of anti-malaria activity in *P. vinckei* by DOXO and ART combination, since none of the mice developed infection up to day 10 and higher EAI index of ART. The mechanism of action artemisinin, involves the breaking of endoperoxide bridge and generating a highly reactive free radical that kills malaria parasites [27,28]. Our previous study has shown that higher antioxidant enzyme, glutathione may be correlated with ART resistance in *P. vinckei* [24,23]. The DOXO enhanced the oxidative stress and showed the synergetic effect with artemisinin in *P. falciparum* [29,30]. Dihydroartemisinin is derivative of artemisinin that also has synergistic anti-cancer activity in the combination with doxorubicin in breast cancer

DOXO (mg/kg)	Arteether (mg/kg)	No. of mice	Parasitemia (mean ± SEM) on day				
			4	7	10	14	17
5	3	6	Nil (6) [#]	Nil (6)	Nil (6)	0.30 (4)	0.44 (0)
--	3	6	0.92 (0)	1.56 (0)	3.66 (0)	2.62 (0)	1.27 (0)
5	--	6	0.92 (0)	1.07 (0)	1.75 (0)	5.15 (0)	2.45 (0)
--	--	6	1.28 (0)	1.54 (0)	1.76 (0)	1.54 (0)	2.94 (0)

Table 1: Response of DOXO in combination with ART against PvAR strain in Swiss mice

[#]Number in parenthesis indicates mice showing nil parasitemia

Drugs	ED ₁₀ (mg/kg)	ED ₅₀ (mg/kg)	ED ₉₀ (mg/kg)	Activity Enhancement Index (AEI)
ART	-	4.49	17.23	-
DOXO	0.39	2.02	3.65	-
ART+DOXO (0.4 mg/kg)	-	3.19	7.92	2.17
ART+ DOXO (2 mg/kg)	-	0.07	1.90	9.07

Table 2: ED₅₀/ED₉₀ of ART and DOXO alone/combination and also showing Activity Enhancement index of ART

cells [31]. The DOXO lowered GSH or GSH reductase levels *in-vitro* cultured rat heart cells [32]. This indicates indicating that ART-DOXO exerts their chemotherapeutic effect by increasing the oxidative stress. This synergistic effect can be largely explained by the fact that ART and DOXO use killing of resistant parasite [33]. Overall, this study give better idea to the possibility of ART drug combination that may be helpful in prolonging the life of drug and a promising lead to reduce the chance of resistance development of artemisinin and its derivative.

Acknowledgments

The authors are grateful to the Director of the CDRI for continued support and encouragement. Technical assistance rendered by Mr. K.K. Singh is gratefully acknowledged. The award of a research fellowship to one of the authors (RC) from CSIR, New Delhi, is also acknowledged.

References

- Meshnick SR, Taylor TE, Kamchonwongpaisan S (1996) Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. *Microbiol Rev* 60: 301-315.
- Meshnick SR (1994) The mode of action of antimalarial endoperoxides. *Trans R Soc Trop Med Hyg* 88: S31-S32.
- Ridley RG (2003) Malaria: to kill a parasite. *Nature* 424: 887-889.
- Dondorp AM, Yeung S, White L, Nguon C, Day N P, et al. (2010) Artemisinin resistance: current status and scenarios for containment. *Nat Rev Microbiol* 8: 272-280.
- Michael OS, Gbotosho GO, Folarin OA, Okuboyejo T, Sowunmi A, et al. (2010) Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. *Malar J* 9: 335.
- Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, et al. (2014) Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. *Malar J* 13: 32.
- Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, et al. (2006) Safety and efficacy of dihydroartemisinin/piperazine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. *Trans R Soc Trop Med Hyg* 100: 1105-1111.
- Kanya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, et al. (2007) Artemether-lumefantrine versus dihydroartemisinin-piperazine for treatment of malaria: a randomized trial. *PLoS Clin Trials* 2: e20.
- WHO (2002) Review of application for inclusion of a drug in the WHO Essential Drugs List: Artemotil and α/β arteether.
- Asthana OP, Srivastava JS, Pandey TK, Vishwanathan KA, Dev V, et al. (2001) Multicentric clinical trials for safety and efficacy evaluation of alpha;beta arteether in complicated P. falciparum malaria. *J Assoc Physicians India* 49: 1155-1160.

11. Pareek A, Nandy A, Kochar D, Patel KH, Mishra SK, et al. (2006) Efficacy and safety of beta-artether and alpha/beta-artether for treatment of acute *Plasmodium falciparum* malaria. *Am J Trop Med Hyg* 75: 139-142.
12. Mukim A, Shukla M, Patel J, Patel H, Naik S, et al. (2011) A phase III clinical trial of alpha, beta-artether injection 150 mg/ml in patients of *P falciparum* malaria. *J Indian Med Assoc* 109: 597-599.
13. Tripathi R, Rizvi A, Pandey SK, Dwivedi H, Saxena JK (2013) Ketoconazole, a cytochrome P(450) inhibitor can potentiate the antimalarial action of alpha/beta artether against MDR *Plasmodium yoelii nigeriensis*. *Acta Trop* 126: 150-155.
14. Chandra R, Puri SK (2015) Arteether resistance reversal by ketoconazole/fluconazole in rodent malaria parasite *Plasmodium vinckei*. *Parasitology Research* 114: 1239-1243.
15. Vathsala PG, Dende C, Nagaraj VA, Bhattacharya D, Das G, et al. (2012) Curcumin-artether combination therapy of *Plasmodium berghei*-infected mice prevents recrudescence through immunomodulation. *PLoS One* 7: e29442.
16. Singh RK (2007) Efficacy of combined treatment with alpha/beta-artether and sulfadoxine-pyrimethamine, for cases of *Plasmodium falciparum* malaria in Jharkhand, India. *Ann Trop Med Parasitol* 101: 271-273.
17. Braña MF, Cacho M, Gradillas A, de Pascual-Teresa B, Ramos A (2001) Intercalators as anticancer drugs. *Curr Pharm Des* 7: 1745-1780.
18. Hickman JA (1992) Apoptosis induced by anticancer drugs. *Cancer Metastasis Rev* 11: 121-139.
19. Kiechle FL, Zhang X (2002) Apoptosis: biochemical aspects and clinical implications. *Clin Chim Acta* 326: 27-45.
20. Yokochi T, Robertson KD (2004) Doxorubicin inhibits DNMT1, resulting in conditional apoptosis. *Mol Pharmacol* 66: 1415-1420.
21. Puri SK, Chandra R (2006) *Plasmodium vinckei*: selection of a strain exhibiting stable resistance to artether. *Exp Parasitol* 114: 129-132.
22. Chandra R, Tripathi LM, Saxena JK, Puri SK (2011) Implication of intracellular glutathione and its related enzymes on resistance of malaria parasites to the antimalarial drug artether. *Parasitol Int* 60: 97-100.
23. Chandra R, Kumar S, Puri SK (2014) Buthionine sulfoximine increases the efficacy of artether antimalarial activity in artether-resistant *Plasmodium vinckei* by glutathione depletion. *Malaria World*.
24. Chandra R, Kumar S, Puri SK (2011) *Plasmodium vinckei*: infectivity of artether-sensitive and artether-resistant parasites in different strains of mice. *Parasitol Res* 109: 1143-1149.
25. Peters W, Ekong R, Robinson BL, Warhurst DC, Pan XQ (1990) The chemotherapy of rodent malaria. XLV. Reversal of chloroquine resistance in rodent and human *Plasmodium* by antihistaminic agents. *Ann Trop Med Parasitol* 84: 541-551.
26. Seifert K, Croft SL (2006) *In vitro* and *in vivo* interactions between miltefosine and other antileishmanial drugs. *Antimicrob Agents Chemother* 50: 73-79.
27. Ittarat W, Sreepian A, Srisarin A, Pathepchtivong K (2003) Effect of dihydroartemisinin on the antioxidant capacity of *P. falciparum*-infected erythrocytes. *Southeast Asian J Trop Med Public Health* 34: 744-750.
28. Antoine T, Fisher N, Amewu R, O'Neill PM, Ward SA, et al. (2014) Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. *J Antimicrob Chemother* 69: 1005-1016.
29. Krungkrai SR, Yuthavong Y (1987) The antimalarial action on *Plasmodium falciparum* of qinghaosu and artesunate in combination with agents which modulate oxidant stress. *Trans R Soc Trop Med Hyg* 81: 710-714.
30. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M (2007) Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. *PLoS One* 2: e693.
31. Wu GS, Lu JJ, Guo JJ, Huang MQ, Gan L, et al. (2013) Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. *Pharmacol Rep* 65: 453-459.
32. Paranka NS, Dorr RT (1994) Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells. *Anticancer Res* 14: 2047-2052.
33. Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. *J Toxicol* 2012: 645460.